参芪扶正注射液联合XELOX方案对晚期胃癌患者的治疗作用

Therapeutic effect of Shenqi Fuzheng injection combined with XELOX scheme on patients with advanced gastric cancer

目的探讨对晚期胃癌患者联合给予参芪扶正注射液和XELOX化疗方案的治疗作用。方法对89例晚期胃癌的临床资料进行回顾分析,其中45例实施参芪扶正注射液联合XELOX化疗,记为A组;44例单纯实施XELOX化疗,记为B组。对比两组疗效、免疫功能变化、不良反应情况。结果 A组肿瘤控制效果分布情况与B组差异显著(P<0.05),且A组临床获益率明显高于B组(P<0.05);A组治疗后CD3^+、CD4^+、CD8^+、CD4^+/CD8^+均基本不变(P>0.05),B组CD3^+、CD4^+、CD4^+/CD8^+均显著降低,且CD8^+显著升高(P<0.05),且治疗后组间均有显著性差异(P<0.05);A组各项不良反应发生率均远低于B组(P<0.05),且前者分级情况与后者对比差异均有统计学意义(P<0.05)。结论对晚期胃癌患者联合给予参芪扶正注射液和XELOX方案具有理想的增效减毒作用。

Objective To discuss the therapeutic effect of combination of Shenqi Fuzheng injection and XELOX chemotherapy for patients with advanced gastric cancer. Methods＇ The data of 89 patients with advanced gastric cancer ret- rospectively analyzed, 45 cases were treated with Shenqi Fuzheng injection combined with XELOX chemotherapy, as the group A, and 44 cases were treated with XELOX chemotherapy, as the group B. The effects, the changes of immune func- tion before and after treatment and adverse reactions in the two groups were compared. Results The distribution of tumor control effect in the group A was significantly different fi＇om that in the group B （P〈0.05）, the clinical benefit rate of the group A was significantly higher than that of the group B （P〈0.05）. The CD3＋, CD4＋, CD8＋, CD4＋/CD8＋ were all unchanged afler treatment in the group A （P〉0.05）, and the CD3＋, CD4＋, CD4＋/CD8＋ in the group B significantly decreased, while the CD8＋ sig- nificantly increased （P〈0.05） and there were significant differences between the two groups after treatment （P〈0.05）. The incidences of adverse reactions in the group A were much lower than those in the group B （P〈0.05）, and the differences in the distributions between the former and the latter were statistically significant （P〈0.05）. Conclusion The combination of Shenqi Fuzheng injection and XELOX for patients with advanced gastric cancer has an ideal synergistic and attenuated effect.